MK-5160
Biological
Merck Sharp & Dohme Corporation
Total Payments
$3.4M
Transactions
43
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $336,873 | 12 | 0 |
| 2017 | $3.1M | 31 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.4M | 43 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Effect of MK-5160 in Subjects with Type 1 and Type 2 Diabetes Mellitus | Merck Sharp & Dohme Corporation | $2.6M | 0 |
| A single rising dose clinical trial to study the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-5160 in healthy subjects | Merck Sharp & Dohme Corporation | $830,997 | 0 |
Top Doctors Receiving Payments for MK-5160
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chula Vista, CA | $3.4M | 43 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $3.4M
- Total Doctors 0
- Transactions 43
About MK-5160
MK-5160 is a biological associated with $3.4M in payments to 0 healthcare providers, recorded across 43 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2018. In 2018, $336,873 was paid across 12 transactions to 0 doctors.
The most common payment nature for MK-5160 is "Unspecified" ($3.4M, 100.0% of total).
MK-5160 is associated with 2 research studies, including "A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Effect of MK-5160 in Subjects with Type 1 and Type 2 Diabetes Mellitus" ($2.6M).